Previous studies have shown that immunosuppression in acute myeloid leukemia (AML) is associated with changes in the adaptive immune compartment. Such changes include the suppression of memory T-cell function 1 and the suppression of Th1 cytokine (TNFa, IL-2 and IFNg)-producing cells. 2 A suppressed immune response in AML is associated with a worse patient outcome and increased risk of relapse, 3 as well as increased risk of infection impairing patient recovery. 4 The over-expression of the immunosuppressive ligand CD200 is also associated with an increased risk of relapse in AML (hazard ratio 1.7); an observation consistent with a hypothesis in which CD200 inhibits clearance of residual disease. 5, 6 As memory T-cell responses are central for tumor immunosurveillance and contribute to prolonged molecular remission, 7 we carried out this study to establish how these responses were affected in AML patients over-expressing CD200 (Supplemental Table S1 ). We initially investigated whether CD200 expression on AML blasts influenced CD8 þ T-cell cytotoxic potential and the frequency of TNFa-, IL-2-and IFNg-producing CD4 þ /CD8 þ memory T-cells (Supplementary Materials and Methods and Supplemental Figure S1 for gating strategy). Using CD107a as a marker of cytotoxic function, AML cells were activated with PMA/ionomycin. We show that the frequency of CD107a þ CD8 þ memory T-cells was significantly reduced by B50% for CD200 hi patients when compared with CD200 lo AML, demonstrating that cytotoxic memory T-cell activity was compromised in CD200 hi patients (Figure 1a) . Furthermore, the frequencies of TNFa-, IL-2-and IFNg-producing CD4 þ memory cells were also reduced by B50% for CD200 hi patients when compared with CD200 lo AML (Figure 1b) , significantly so in the case of IL-2 and IFNg. Interestingly, CD200 lo patients displayed a higher IFNg response, not only with respect to CD200 hi patients but also in comparison to healthy donors, suggesting a role for this cytokine in AML, which is attenuated by CD200. No difference was observed for TNFa-, IL-2-and IFNg-producing CD8 þ memory cells between CD200 hi , CD200 lo and healthy donors (data not shown). CD200 has also been reported to mediate suppression of the Th1 response in chronic lymphocytic leukemia as well as solid tumors, 8, 9 suggesting that CD200-mediated Th1 suppression is a central mechanism in cancer immunomodulation.
The ability to simultaneously produce TNFa, IL-2 and IFNg is an important indicator of 'T-cell quality' in anti-tumor/viral responses. 10 We therefore simultaneously measured the production of all these cytokines in CD200
hi and CD200 lo patients after PMA/ionomycin stimulation (Supplemental Figure S1 ). A significant reduction (30%) in CD4 þ memory T-cells capable of simultaneously producing TNFa, IL-2 and IFNg was observed in CD200 hi compared with CD200 lo AML patients ( Figure 1c ). Although a similar reduction was observed within the CD8 þ memory cells, the changes in this subpopulation were less consistent and were not statistically significant (Supplemental Figure S2 ). To assess if CD200 expression on AML blasts influences the memory Th1 response through an antigen-specific mechanism, we compared T-cell responses with common microbial recall
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Accepted article preview online 20 March 2012; advance online publication, 13 April 2012 Letters to the Editor antigens (PPP) by ELISPOT (Supplementary Materials and Methods). 11 We observed a significant 75% reduction in the frequency of IFNg-secreting T-cells towards PPP in CD200 hi vs CD200 lo AML (Figures 1d and e). CD200 expression level did not influence the overall frequency of CD3 þ lymphocytes (Supplemental Figure S3) , demonstrating that the difference observed in these cohorts was due to T-cell inhibition in CD200 hi patients and not due to a decrease in overall T-cell frequency or increase in AML blasts. Thus, we show for the first time (in any context) that CD200 expression in AML is associated with the suppression of Th1 memory T-cell quality and function. Not only does this finding demonstrate that the memory T-cell response in CD200 hi patients is suppressed through an antigen-specific mechanism, but suggests that CD200 expression may exacerbate the susceptibility of leukemia patients to common microbial infections, which may impair patient recovery. 4 This notion is supported by a study from Snelgrove et al., who demonstrated in a murine model that CD200 expression suppresses T-cell responses towards influenza. 12 To demonstrate that this immunosuppression was functionally driven by CD200, we asked whether blocking CD200 could also recover the AML Th1 memory T-cell response. Figures 2a and b show a significant recovery of memory T-cells secreting IFNg for CD200 hi patients in an ELISPOT assay, raising the possibility that AML blast CD200 was directly interacting with memory T-cells via CD200R. Flow cytometric data confirmed CD200R expression on memory T-cells from AML patients (Figure 2c ), supporting previous literature using healthy subjects. 13 To rule out the possibility of indirect suppression through antigenpresenting cells, we next carried out a refined assay in which a CD4 þ T-cell clone (Belx2) 14 was co-cultured with K562 cells, which differed solely in their expression of CD200 (Supplemental Figure  S4) . 15 We showed a significantly impaired TNFa response in CD200 hi K562 cells compared with control co-cultures (Figure 2d ). We also observed a significant suppression in IL-2 and IFNg production with a loss of multi-functionality in terms of TNFa and IFNg production in the presence of CD200 þ cells (Supplemental Figure S4) , though the frequency of Belx2 cells producing IFNg and IL-2 was minimal compared with TNFa under these assay conditions. Adding anti-CD200 to the CD3/CD28-stimulated assay could significantly recover TNFa production in CD200 þ cocultures to the same level as CD200 À co-cultures (Figure 2d ), thus demonstrating that blockade of CD200 alone is sufficient to recover memory T-cell activity. The data also show that the intensity of TNFa was decreased (though not significantly) in CD200 þ cultures, which was fully recovered by the addition of anti-CD200 (Figure 2e ). This finding indicates that CD200 can suppress both the magnitude and intensity of the memory Th1 response in AML and that blocking CD200 in this disease may be therapeutically advantageous. Previously, we have shown that CD200 on AML cells directly impairs NK cell function. 15 However, CD200 expression may not always promote immunosuppression in every context. One study using a CD200 þ mouse plasmacytomal model showed that CD200 had the capacity to decrease production of the suppressive Figure 1 . Cytotoxic T-cell response and Th1 memory/recall response in CD200 hi and CD200 lo AML patients. AML patient cytotoxic and intracellular Th1 cytokine memory T-cell responses were measured by flow cytometry following PMA/ionomycin stimulation (for full methods and flow cytometric gating strategies see Supplementary Materials and Methods and Supplemental Figure S1 ). (a) Summary data illustrating a significant difference in CD107a þ CD8 þ memory T-cells between CD200 hi and CD200 lo AML patients. (b) The production of TNFa, IL-2 or IFNg for CD200 hi , CD200 lo and healthy donors for CD4 þ memory T-cells. (c) Pie charts summarizing the proportion of CD4 þ and CD8 þ memory cells capable of producing one (1 ¼ TNFa, IL-2 or IFNg), two (2 ¼ TNFa/Il-2, TNFa/IFNg or IFNg/IL-2) or three (3 ¼ TNFa/IL-2/IFNg) cytokines simultaneously for CD200 hi or CD200 lo (refer to Supplemental Figure S1 for Boolean analysis). cytokine IL-10 from tumor-associated myeloid cells resulting in an improved anti-tumor response. 16 Whether this mechanism exists in human AML remains to be elucidated. Taken together, the data presented here this suggests that at diagnosis, when the disease burden is high, the main mechanism of CD200 is to drive immunosuppression through direct interaction of CD200 on leukemia cells with CD200R on cells of the adaptive immune system. The situation may be different following reduction of tumor burden post-chemotherapy, where the influence of Treg cells may become a dominant factor in immunosuppression. 17 In conclusion, we show for the first time that CD4
þ Th1 memory and memory cytotoxic responses are significantly compromised in CD200
hi AML patients, which may contribute to the increased risk of relapse and worse overall survival observed in these patients. Most importantly we demonstrate that CD200 on leukemia cells directly suppresses T-cell responses, supporting the use of CD200-blocking therapy for the treatment of AML. þ memory T-cells, the CD4 þ memory T-cell clone; Belx2 were co-cultured with control or CD200 þ K562 cells. The percentage of TNFa-producing Belx2 T-cell clones in co-culture assays in response to CD3/CD28 costimulation was measured by flow cytometry following intracellular staining. Summary data illustrates the frequency of TNFa-producing T-cells in CD200 þ and CD200 -K562 co-cultures þ / À anti-CD200. (e) Summary data illustrating MFI of the TNFa þ T-cell population in CD200 þ and CD200 -K562 co-cultures þ / À anti-CD200. Data represents mean ± 1 s.d., n ¼ 6. *Po0.05, analyzed by one-tailed paired t-test. 1-4 RUNX1 encodes a transcription factor essential for definitive hematopoiesis, containing an amino-terminal DNA binding domain (RUNT) and a carboxyl-terminal transactivation domain (TA). RUNX1 mutations act by either a dominant negatively interfering mechanism or by haploinsufficiency. Constitutional deletions spanning RUNX1 have been reported in isolated congenital or syndromic thrombocytopenia, stipulating copy number analysis (CNA) of RUNX1 next to sequencing. [5] [6] [7] [8] Given clinical heterogeneity, vigilance in diagnosing FPD/AML is required, reducing the risk of stem cell transplantation (SCT) with carrier siblings. 2, 3 Furthermore, the identification of a RUNX1 abnormality and the elucidation of the underlying pathogenomic mechanism may have implications for genetic counseling for recurrence risk of FPD/AML. This study included two families with classical FPD/AML and one seemingly isolated case with storage pool deficiency (SPD), thrombocytopenia and AML. All patients were of Caucasian origin. For detailed clinical and hematological characteristics of the pedigrees, we refer to Supplemental Table S1 . RUNX1 was analyzed by Sanger sequencing of coding exons 2-9 of gDNA using intronic primers.
In pedigree 1, gDNA was extracted from peripheral blood (PB) of III-2, III-3 and IV-1. A c.508 G4A was detected in RUNX1c exon 4 in affected family members III-2 and IV-1 causing an amino-acid substitution p.Gly170Arg (Figure 1) , which is located in the RUNT domain. Somatic mutations within this codon have been reported in sporadic AML/MDS. 9 RUNT domain mutations have been related to a negatively interfering mechanism in FPD/AML. 10 The unaffected mother (III-3) as well as DNA from 100 controls lacked the mutation. No DNA was available of the affected daughter V-2 and of IV-3 diagnosed with AML at age of 3 years.
In pedigree 2, sequencing of PB gDNA of III-1, III-5, IV-5 and IV-6 revealed a c.784C4T substitution in RUNX1c exon 6 in all four affected family members causing a premature stop (p.Gln262X) that would result in a truncated RUNX1 protein lacking the TA domain. DNA from 138 controls lacked the mutation. Similar mutations in FPD/AML and sporadic MDS/AML have been reported previously. 3, 10 Interestingly, III-5 developed refractory anemia with excess blast with acquired trisomy 21, recurrently reported in FPD/AML. 2, 4 In the index case of pedigree 3 (III-5), sequencing of RUNX1 on DNA of leukemic bone marrow (BM) did not reveal mutations. gDNA was analyzed using a 105K oligonucleotide array (Agilent, Santa Clara, CA, USA), Oxford design, Amadid 0190015) and the Infinium HumanHap370 Genotyping BeadChip array (Illumina Inc., San Diego, CA, USA) containing 370 000 SNPs with a median probe spacing of 8 kb for copy number changes of RUNX1. These analyses did not disclose unbalance of RUNX1. Uniparental disomy of any chromosome was excluded.
Considering a possible RUNX1 structural abnormality, FISH analysis on leukemic BM was performed, revealing a cryptic t(16;21)(p13;q22) with RUNX1 locus rearrangement in 15 metaphases and 200 interphases (Figure 2a ). This seminal observation with the patient's hematological history prompted us to investigate RUNX1 status in non-hematopoietic tissues. Interphase FISH analyses on cells from urinary tract epithelium (endoderm) and buccal mucosa (ectoderm), showed RUNX1 locus rearrangement in 86% and 41% of interphases, Accepted article preview online 20 March 2012; advance online publication, 13 April 2012
